Form 4: Revance Therapeutics Director Jill Beraud Reports Acquisition of Shares and Stock Options

Director Jill Beraud reports acquisition of 15,000 shares of common stock and 23,458 stock options in Revance Therapeutics, Inc.

Summary

• On May 1, 2024, Jill Beraud, a director of Revance Therapeutics, Inc., acquired 15,000 shares of common stock and 23,458 stock options.
• The common stock was acquired at a price of $0.
• These acquisitions were reported on a Form 4 filing with the SEC.
• Following the transaction, Beraud directly owns 43,606 shares of common stock.
• The stock options have an exercise price of $3.795 and expire on April 30, 2034.
• The shares and options vest on the earlier of May 1, 2025, or the day before the next annual stockholder meeting, contingent on continuous service as a director.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of insider transactions. The acquisition of shares and options by a director can be seen as a slightly positive sign, but it's not a major event.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The vesting of the shares and options is contingent on the director's continuous service, suggesting a commitment to the company.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for insights into management's confidence in the company's prospects.

Comparison to Industry Standards

• Director compensation packages often include stock options and restricted stock awards to align their interests with those of shareholders.
• The vesting schedule of one year is a fairly standard practice for such grants.
• The exercise price of $3.795 for the stock options is a standard market rate.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it signals director confidence.
• The transaction has no impact on employees, customers, suppliers or creditors.

Key Dates

Keywords

Revance Therapeutics, RVNC, Jill Beraud, Director, Stock Options, Common Stock, SEC Form 4, Beneficial Ownership, Acquisition